Specify a stock or a cryptocurrency in the search bar to get a summary
Adynxx Inc
ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California. Address: 100 Pine Street, San Francisco, CA, United States, 94111
Analytics
WallStreet Target Price
2.8 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ADYX
Dividend Analytics ADYX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
-10 %Dividend History ADYX
Stock Valuation ADYX
Financials ADYX
Results | 2019 | Dynamics |